Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4+Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited Settings | Zendy

David B. Meya | Zendy; Yukari C. Manabe | Zendy; Barbara Castelnuovo | Zendy; Bethany Cook | Zendy; Ali Elbireer | Zendy; Andrew Kambugu | Zendy; Moses R. Kamya | Zendy; Paul R. Bohjanen | Zendy; David R. Boulware | Zendy

Open Access

Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4⁺Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited Settings

Author(s) -

David B. Meya,

Yukari C. Manabe,

Barbara Castelnuovo,

Bethany Cook,

Ali Elbireer,

Andrew Kambugu,

Moses R. Kamya,

Paul R. Bohjanen,

David R. Boulware

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/655143

Subject(s) - medicine , fluconazole , subclinical infection , cryptococcosis , confidence interval , prospective cohort study , immunology , antifungal , dermatology

Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research